Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens.

Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr.

Vaccine. 2012 Jan 5;30(2):307-16. doi: 10.1016/j.vaccine.2011.10.094. Epub 2011 Nov 8.

PMID:
22079079
[PubMed - indexed for MEDLINE]
2.

Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y.

Vaccine. 2012 Nov 6;30(48):6871-7. doi: 10.1016/j.vaccine.2012.09.007. Epub 2012 Sep 16.

PMID:
22989689
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model.

Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker JR.

Hum Vaccin. 2010 Jul;6(7):585-94.

PMID:
20421727
[PubMed - indexed for MEDLINE]
Free Article
4.

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.

Vaccine. 2006 Jan 16;24(3):254-62. Epub 2005 Aug 15.

PMID:
16129526
[PubMed - indexed for MEDLINE]
5.

Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant.

Hamouda T, Sutcliffe JA, Ciotti S, Baker JR Jr.

Clin Vaccine Immunol. 2011 Jul;18(7):1167-75. doi: 10.1128/CVI.00035-11. Epub 2011 May 4.

PMID:
21543588
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.

de B, Zanasi A, Ragusa S, Glück R, Herzog C.

Clin Ther. 2002 Jan;24(1):100-11.

PMID:
11833825
[PubMed - indexed for MEDLINE]
7.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

PMID:
18786689
[PubMed - indexed for MEDLINE]
Free Article
8.

Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.

Kimoto T, Mizuno D, Takei T, Kunimi T, Ono S, Sakai S, Kido H.

Influenza Other Respir Viruses. 2013 Nov;7(6):1218-26. doi: 10.1111/irv.12124. Epub 2013 May 26.

PMID:
23710832
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.

Vaccine. 2006 May 1;24(18):3990-4006. Epub 2005 Dec 27.

PMID:
16516356
[PubMed - indexed for MEDLINE]
10.

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.

Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.

Vaccine. 2012 Jan 5;30(2):466-74. doi: 10.1016/j.vaccine.2011.10.058. Epub 2011 Oct 31.

PMID:
22051136
[PubMed - indexed for MEDLINE]
11.

Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.

Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K, Kitamura S, Shiota H, Kido H.

Vaccine. 2009 Sep 18;27(41):5620-7. doi: 10.1016/j.vaccine.2009.07.024. Epub 2009 Jul 30.

PMID:
19647064
[PubMed - indexed for MEDLINE]
12.

The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.

Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.

Vaccine. 2010 Sep 7;28(39):6491-7. doi: 10.1016/j.vaccine.2010.07.001. Epub 2010 Jul 15.

PMID:
20637767
[PubMed - indexed for MEDLINE]
13.

Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.

Mizuno D, Ide-Kurihara M, Ichinomiya T, Kubo I, Kido H.

J Immunol. 2006 Jan 15;176(2):1122-30.

PMID:
16394001
[PubMed - indexed for MEDLINE]
Free Article
14.

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.

Vaccine. 2009 Dec 30;27 Suppl 6:G60-6. doi: 10.1016/j.vaccine.2009.10.031.

PMID:
20006142
[PubMed - indexed for MEDLINE]
15.

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB.

Vaccine. 2007 Jul 20;25(29):5367-73. Epub 2007 May 22.

PMID:
17559990
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
[PubMed - indexed for MEDLINE]
17.

Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.

Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z.

Vaccine. 2004 Jun 30;22(20):2566-77.

PMID:
15193382
[PubMed - indexed for MEDLINE]
18.

Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.

Gupta NK, Tomar P, Sharma V, Dixit VK.

Vaccine. 2011 Nov 8;29(48):9026-37. doi: 10.1016/j.vaccine.2011.09.033. Epub 2011 Sep 20.

PMID:
21939718
[PubMed - indexed for MEDLINE]
19.

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.

Hashigucci K, Ogawa H, Ishidate T, Yamashita R, Kamiya H, Watanabe K, Hattori N, Sato T, Suzuki Y, Nagamine T, Aizawa C, Tamura S, Kurata T, Oya A.

Vaccine. 1996 Feb;14(2):113-9.

PMID:
8852406
[PubMed - indexed for MEDLINE]
20.

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.

Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M, Tashiro M, Sata T, Kurata T, Hasegawa H.

Microbes Infect. 2006 Oct;8(12-13):2706-14. Epub 2006 Aug 28.

PMID:
16968669
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk